Sepsis is defined as a severe condition derived from a primary infection site. In patients with sepsis, as a rule, a primary infected focus should be investigated, and treatment must be performed in accordance with the site of infection and condition. As the most important point, physicians must consider the start of antimicrobial chemotherapy for sepsis, fatal organ failure, in the early phase (within 1 hour).
Sepsis is one of the most serious conditions among all infectious diseases. To establish a sepsis treatment system as the basis of bacterial infection treatment, knowledge regarding infectious disease medicine/chemotherapeutics must be collected. Due to the recent appearance of various antimicrobial-drug-resistant bacteria, it is necessary to be flexible with strategies to treat bacterial infection. This is not exceptional in the field of sepsis. It is also necessary to manage other such infections, considering the involvement of antimicrobial-drug-resistant bacteria, including MRSA (Methicillin Resistant Staphylococcus Aureus) and ESBL (Extended Spectrum β-lactamase)-producing bacteria. Antimicrobial-drug-resistant bacteria have been routinely detected in patients not only with nosocomial but also with community-acquired infection.
This is not “new” information; however, with the current COVID pandemic still thwarting our efforts to return to “normal,” it is a good reminder that scientists are still researching the types of disease processes that can lead to negative outcomes in our residents. Be sure your staff are alert to the signs of early infection and are performing sepsis screening on those residents with active infection and/or change in condition.
Stay the course, stay well, mask up, get vaccinated, and stay tuned!